News Column

Studies from Technical University Further Understanding of Clinical Trials and Studies

June 23, 2014

By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Clinical Research are discussed in a new report. According to news originating from Braunschweig, Germany, by NewsRx correspondents, research stated, "The contribution describes the transfer from a batch to a micro-continuous process for the production of stable solid lipid nanoparticles as drug carrier systems. Solid lipid nanoparticles are commonly prepared batch-wise often resulting in poorly defined product qualities with regard to the polymorphic state of their lipid matrix."

Our news journalists obtained a quote from the research from Technical University, "In order to obtain solid lipid nanoparticle dispersions that meet the requirements for an acceptable pharmaceutical product, the manufacture of reproducible product qualities preferably containing the stable crystal form of the respective matrix lipid is necessary. These requests are addressed by the continuous preparation process of solid lipid nanoparticles. A four step feasibility study for the standardized evaluation whether or not a colloidal lipid dispersion is suitable for continuous crystallization of the particles resulting in stable crystal forms is presented. The process is based on the continuous crystallization and subsequent thermal treatment of differently stabilized, tripalmitin based nanoparticle formulations in microstructured devices."

According to the news editors, the research concluded: "The successful production of the stable crystal form by means of a continuous process chain is shown for a dispersion stabilized with a blend of hydrogenated soybean lecithin and sodium glycocholate."

For more information on this research see: Controlled polymorphic transformation of continuously crystallized solid lipid nanoparticles in a microstructured device: A feasibility study. European Journal of Pharmaceutics and Biopharmaceutics, 2014;86(3):324-331. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier -; European Journal of Pharmaceutics and Biopharmaceutics -

The news correspondents report that additional information may be obtained from M. Schoenitz, Technical University Carolo Wilhelmina, Inst Pharmaceut Technol, D-38106 Braunschweig, Germany. Additional authors for this research include S. Joseph, A. Nitz, H. Bunjes and S. Scholl (see also Clinical Research).

Keywords for this news article include: Europe, Germany, Braunschweig, Nanoparticle, Nanotechnology, Clinical Research, Emerging Technologies, Clinical Trials and Studies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Clinical Trials Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters